Together Everyone Achieves More (TEAM) Trial (TEAM)

April 29, 2026 updated by: Allison M. Sweeney, University of South Carolina

The Together Everyone Achieves More Physical Activity Trial

The Together Everyone Achieve More (TEAM) Physical Activity trial evaluates the efficacy of a group-based social affiliation intervention (vs. a standard group-delivered physical activity comparison program) for increasing physical activity among inactive African American women. Using a group cohort randomized design implemented at community centers across five years, the primary aim of this study is to evaluate the efficacy of the 10-week TEAM-PA group-based intervention (vs. comparison program) on increasing daily total physical activity from baseline to post-intervention and maintenance at a 6-month follow-up.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
360

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • South Carolina
      • Columbia, South Carolina, United States, 29208
        • College of Nursing, University of South Carolina

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • at least 18 years of age
  • self-identifying as an African American or Black female
  • engaging in < 60 minutes of moderate to vigorous physical activity per week for the last three months

Exclusion Criteria:

  • having a cardiovascular or orthopedic condition that would limit physical activity (including walking with a cane/walker)
  • currently pregnant or planning to become pregnant in the next 2 months
  • uncontrolled blood pressure (systolic >180 mmHg/diastolic > 110 mmHg)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Intervention
This group will receive a 10-week group-based intervention program.
Behavioral: Intervention
Participants receiving the intervention will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting and includes a focus on cultural topics related to collectivism. Participants receive FitBits to track their physical activity and through the FitBit mobile app are connected to their group members to encourage communication and social support.
Active Comparator: Comparison
The group will receive a 10-week group-based comparison program.
Behavioral: Comparison
Participants receiving the comparison program will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, group walking program, and individual-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting only (and no focus on collectivism). Participants receive FitBits to track their physical activity, but are not connected to their group members on the mobile app.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Total Physical Activity
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
Average minutes of total physical activity (PA) per day; Objective assessments of total PA will be obtained with ActiGraph accelerometers. Participants will wear the monitor on the non-dominant wrist for 7 consecutive days. The investigators will evaluate whether there is a change in minutes of total PA per day from baseline to 10 weeks and maintenance at 6 months post-intervention, and whether there are group differences between the intervention and comparison programs.
Baseline, post-intervention (10 weeks), and 6 months post-intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Percentage meeting national guidelines for weekly moderate to vigorous physical activity
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
Percentage of participants with at least 150 minutes of moderate physical activity and/or 75 minutes of vigorous physical activity per week; Objective assessments of minutes of moderate to vigorous physical activity will be obtained with ActiGraph accelerometers. The investigators will evaluate whether there is a change in the percentage of participants meeting national guidelines from baseline to 10 weeks and maintenance at 6 months post-intervention, and whether there are group differences between the intervention and comparison programs.
Baseline, post-intervention (10 weeks), and 6 months post-intervention
Light Physical Activity
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
Average minutes of light physical activity (PA) per day; Objective assessments of light PA will be obtained with ActiGraph accelerometers. The investigators will evaluate whether there is a change in daily minutes of light PA from baseline to 10 weeks and maintenance at 6 months post-intervention, and whether there are group differences between the intervention and comparison programs.
Baseline, post-intervention (10 weeks), and 6 months post-intervention
Sedentary Behavior
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
Average minutes of sedentary behavior per day; Objective assessments of sedentary behavior will be obtained with ActiGraph accelerometers. The investigators will evaluate whether there is a change in sedentary behavior from baseline to 10 weeks and maintenance at 6 months post-intervention, and whether there are group differences between the intervention and comparison programs.
Baseline, post-intervention (10 weeks), and 6 months post-intervention
Body Mass Index (BMI)
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
Height (cm) and weight (kg) will be measured using a stadiometer and medical-grade scale. Scores will be used to calculate BMI (kg/m^2). The investigators will evaluate whether there is a change in BMI from baseline to 10 weeks and maintenance at 6 months post-intervention, and whether there are group differences between the intervention and comparison programs.
Baseline, post-intervention (10 weeks), and 6 months post-intervention
Blood Pressure
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
Systolic and diastolic blood pressure will be measured using an automatic blood pressure machine. The investigators will evaluate whether there is a change in blood pressure from baseline to 10 weeks and maintenance at 6 months post-intervention, and whether there are group differences between the intervention and comparison programs.
Baseline, post-intervention (10 weeks), and 6 months post-intervention
Two-Minute Walk Test (Walking Speed)
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
Starting from a standing position, participants are asked to walk as far as they can in a safe manner for two minutes over a flat out and back 50 feet course. The distance traveled to the nearest foot is recorded.
Baseline, post-intervention (10 weeks), and 6 months post-intervention

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Reciprocal Social Support for Physical Activity
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
The Support for Exercise Scale (Sallis et al 1987) will be adapted [12 items; 1 = Never; 6 = Very Frequently ] to measure providing and receiving of social support among group members. Mean composite scores will be calculated (ranging from 1-6), with higher numbers indicate greater social support.
Baseline, post-intervention (10 weeks), and 6 months post-intervention
Group Cohesion among Group Members
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
Two subscales (Individual Attraction to the Group - Social; Group Integration - Social) from the Physical Activity Group Environment Questionnaire (Estrabrooks et al 2000) [10 items; 1 = Strongly Disagree, 6= Strongly Agree] will be used to assess group cohesion among group members. Mean composite scores will be calculated (ranging from 1-6), with higher numbers indicate greater group cohesion.
Baseline, post-intervention (10 weeks), and 6 months post-intervention
Group Interactions (Communication, Cooperation, Friendly Competition)
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
Items developed by Harden et al (2014) [12 items; 1 = Strongly Disagree, 6= Strongly Agree] will be used to assess communication, cooperation, and friendly competition among group members. Mean composite scores will be calculated (ranging from 1-6), with higher numbers indicate more positive group interactions.
Baseline, post-intervention (10 weeks), and 6 months post-intervention
Collective Efficacy for Physical Activity among Group Members
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
The Unity subscale from the Collective Efficacy Questionnaire for Sports (Short et al. 2005) will be adapted [4 items; 5-point, 1 = Not at all confident, 5 = Extremely confident] to assess collective efficacy for physical activity among group members. A mean composite score will be calculated (ranging from 1-5), with higher numbers indicating greater collective efficacy.
Baseline, post-intervention (10 weeks), and 6 months post-intervention
Relatedness among Group Members
Time Frame: Baseline, post-intervention (10 weeks), and 6 months post-intervention
The Need for Relatedness Scale (Richer & Vallerand, 1998) will be used [10 items; 1 = Strongly Disagree, 6= Strongly Agree] to assess relatedness among group members. A mean composite score will be calculated (ranging from 1-6), with higher numbers indicating greater relatedness.
Baseline, post-intervention (10 weeks), and 6 months post-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of South Carolina

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Heart, Lung, and Blood Institute (NHLBI)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 12, 2022

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 22, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 24, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 29, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 5, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 29, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Pro00113152
  • R01HL160618 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The investigators plan to share the Statistical Analysis Plan and Informed Consent Form.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings